Taken together, our results support the idea that inhibition of PAX3-FOXO1 phosphorylation is a viable avenue for novel therapy development that could be applicable to translocation-positive ARMS tumors. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.